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Abstract
In this article, we propose actions that will help society accept the benefits of enhancement, given
appropriate research and evolved regulation. Prescription drugs are regulated as such not for their
enhancing properties but primarily for considerations of safety and potential abuse. Still, cognitive
enhancement has much to offer individuals and society, and a proper societal response will involve
making enhancements available while managing their risks.
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COMMENTARY
Towards responsible use of cognitiveenhancing drugs by the healthy
oday, on university campuses around
the world, students are striking deals to
buy and sell prescription drugs such as
Adderall and Ritalin — not to get high, but to
get higher grades, to provide an edge over their
fellow students or to increase in some measurable way their capacity for learning. These
transactions are crimes in the United States,
punishable by prison.
Many people see such penalties as appropriate, and consider the use of such drugs to
be cheating, unnatural or dangerous. Yet one
survey1 estimated that almost 7% of students in
US universities have used prescription stimulants in this way, and that on some campuses,
up to 25% of students had used them in the
past year. These students are early adopters of
a trend that is likely to grow, and indications
suggest that they’re not alone2.
In this article, we propose actions that will
help society accept the benefits of enhancement, given appropriate research and evolved
regulation. Prescription drugs are regulated as
such not for their enhancing properties but primarily for considerations of safety and potential
abuse. Still, cognitive enhancement has much
to offer individuals and society, and a proper
societal response will involve making enhancements available while managing their risks.

C. GALLAGHER/SPL

Society must respond to the growing demand for cognitive enhancement. That response must start by
rejecting the idea that ‘enhancement’ is a dirty word, argue Henry Greely and colleagues.

T

Paths to enhancement
Many of the medications used to treat psychiatric and neurological conditions also improve
the performance of the healthy. The drugs most
commonly used for cognitive enhancement at
present are stimulants, namely Ritalin (methyphenidate) and Adderall (mixed amphetamine
salts), and are prescribed mainly for the treatment of attention deficit hyperactivity disorder
(ADHD). Because of their effects on the catecholamine system, these drugs increase executive functions in patients and most healthy
normal people, improving their abilities to
focus their attention, manipulate information
in working memory and flexibly control their
responses3. These drugs are widely used therapeutically. With rates of ADHD in the range of
4–7% among US college students using DSM
criteria4, and stimulant medication the standard therapy, there are plenty of these drugs on
702

Adderall is one of several drugs
increasingly used to enhance
cognitive function.

campus to divert to enhancement use.
A newer drug, modafinil (Provigil), has also
shown enhancement potential. Modafinil is
approved for the treatment of fatigue caused by
narcolepsy, sleep apnoea and shift-work sleep
disorder. It is currently prescribed off label for a
wide range of neuropsychiatric and other medical conditions involving fatigue5 as well as for
healthy people who need to stay alert and awake
when sleep deprived, such as physicians on night
call6. In addition, laboratory studies have shown
that modafinil enhances aspects of executive
function in rested healthy adults, particularly
inhibitory control7. Unlike Adderall and Ritalin, however, modafinil prescriptions are not
common, and the drug is consequently rare on
the college black market. But anecdotal evidence
and a readers’ survey both suggest that adults
sometimes obtain modafinil from their physicians or online for enhancement purposes2.
A modest degree of memory enhancement
is possible with the ADHD medications just
mentioned as well as with medications developed for the treatment of Alzheimer’s disease
such as Aricept (donepezil), which raise levels
of acetylcholine in the brain8. Several other
compounds with different pharmacological
actions are in early clinical trials, having shown
positive effects on memory in healthy research
subjects (see, for example, ref. 9). It is too early
to know whether any of these new drugs will

be proven safe and effective, but if one is it will
surely be sought by healthy middle-aged and
elderly people contending with normal agerelated memory decline, as well as by people
of all ages preparing for academic or licensure
examinations.

Favouring innovation
Human ingenuity has given us means of enhancing our brains through inventions such as written language, printing and the Internet. Most
authors of this Commentary are teachers and
strive to enhance the minds of their students,
both by adding substantive information and by
showing them new and better ways to process
that information. And we are all aware of the
abilities to enhance our brains with adequate
exercise, nutrition and sleep. The drugs just
reviewed, along with newer technologies such
as brain stimulation and prosthetic brain chips,
should be viewed in the same general category
as education, good health habits, and information technology — ways that our uniquely innovative species tries to improve itself.
Of course, no two enhancements are equivalent in every way, and some of the differences
have moral relevance. For example, the benefits of education require some effort at selfimprovement whereas the benefits of sleep do
not. Enhancing by nutrition involves changing
what we ingest and is therefore invasive in a way
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that reading is not. The opportunity to benefit presumption that mentally competent adults
from Internet access is less equitably distributed should be able to engage in cognitive enhancethan the opportunity to benefit from exercise. ment using drugs.
Cognitive-enhancing drugs require relatively
little effort, are invasive and for the time being Substantive concerns and policy goals
are not equitably distributed, but none of these All technologies have risks as well as benefits.
provides reasonable grounds for prohibition. Although we reject the arguments against
Drugs may seem distinctive among enhance- enhancement just reviewed, we recognize at
ments in that they bring about their effects by least three substantive ethical concerns.
altering brain function, but in reality so does any
The first concern is safety. Cognitive enhanceintervention that enhances cognition. Recent ments affect the most complex and important
research has identified beneficial neural changes human organ, and the risk of unintended side
engendered by exercise10, nutrition11 and sleep12, effects is therefore both high and consequenas well as instruction13 and reading14. In short, tial. Although regulations governing medicinal
cognitive-enhancing drugs seem morally equiv- drugs ensure that they are safe and effective for
their therapeutic indications, there is no equivalent to other, more familiar, enhancements.
Many people have doubts about the moral alent vetting for unregulated ‘off label’ uses,
status of enhancement drugs for reasons rang- including enhancement uses. Furthermore,
ing from the pragmatic to the philosophical, acceptable safety in this context depends on
including concerns about short-circuiting the potential benefit. For example, a drug that
personal agency and undermining the value of restored good cognitive functioning to people
human effort15. Kass16, for example, has written with severe dementia but caused serious adverse
of the subtle but, in his view, important differ- medical events might be deemed safe enough to
ences between human enhancement through prescribe, but these risks would be unacceptable
biotechnology and through more traditional for healthy individuals seeking enhancement.
means. Such arguments have been persuasively
Enhancement in children raises additional
rejected (for example, ref. 17). Three arguments issues related to the long-term effects on the
against the use of cognitive enhancement by developing brain. Moreover, the possibility of
the healthy quickly bubble to the surface in raising cognitive abilities beyond their spemost discussions: that it is cheating, that it is cies-typical upper bound may engender new
unnatural and that it amounts to drug abuse.
classes of side effects. Persistence of unwanted
In the context of sports, pharmacological recollections, for example, has clearly negative
performance enhancement is
effects on the psyche18.
indeed cheating. But, of course,
An evidence-based approach
“We should welcome
it is cheating because it is
is required to evaluate the
new methods of
risks and benefits of cogniagainst the rules. Any good set
improving our brain
tive enhancement. At a miniof rules would need to distinmum, an adequate policy
guish today’s allowed cognitive
function.”
should include mechanisms
enhancements, from private
tutors to double espressos, from the newer for the assessment of both risks and benefits for
methods, if they are to be banned.
enhancement uses of drugs and devices, with
As for an appeal to the ‘natural’, the lives of special attention to long-term effects on develalmost all living humans are deeply unnatural; opment and to the possibility of new types of
our homes, our clothes and our food — to say side effects unique to enhancement. But such
nothing of the medical care we enjoy — bear considerations should not lead to an insistlittle relation to our species’ ‘natural’ state. ence on higher thresholds than those applied to
Given the many cognitive-enhancing tools we medications.
accept already, from writing to laptop computWe call for an evidence-based approach to
ers, why draw the line here and say, thus far but the evaluation of the risks and benefits of cogno further?
nitive enhancement.
As for enhancers’ status as drugs, drug abuse
The second concern is freedom, specifically
is a major social ill, and both medicinal and freedom from coercion to enhance. Forcible
recreational drugs are regulated because of medication is generally reserved for rare cases in
possible harms to the individual and society. which individuals are deemed threats to themBut drugs are regulated on a scale that subjec- selves or others. In contrast, cognitive enhancetively judges the potential for harm from the ment in the form of education is required for
very dangerous (heroin) to the relatively harm- almost all children at some substantial cost to
less (caffeine). Given such regulation, the mere their liberty, and employers are generally free to
fact that cognitive enhancers are drugs is no require employees to have certain educational
reason to outlaw them.
credentials or to obtain them. Should schools
Based on our considerations, we call for a and employers be allowed to require pharma-

OPINION

ceutical enhancement as well? And if we answer
‘no’ to this question, could coercion occur indirectly, by the need to compete with enhanced
classmates and colleagues?
Questions of coercion and autonomy are
particularly acute for military personnel and
for children. Soldiers in the United States
and elsewhere have long been offered stimulant medications including amphetamine
and modafinil to enhance alertness, and in
the United States are legally required to take
medications if ordered to for the sake of their
military performance19. For similar reasons,
namely the safety of the individual in question
and others who depend on that individual in
dangerous situations, one could imagine other
occupations for which enhancement might be
justifiably required. A hypothetical example is
an extremely safe drug that enabled surgeons
to save more patients. Would it be wrong to
require this drug for risky operations?
Appropriate policy should prohibit coercion
except in specific circumstances for specific
occupations, justified by substantial gains in
safety. It should also discourage indirect coercion. Employers, schools or governments
should not generally require the use of cognitive enhancements. If particular enhancements are shown to be sufficiently safe and
effective, this position might be revisited for
those interventions.
Children once again represent a special case
as they cannot make their own decisions. Comparisons between estimates of ADHD prevalence and prescription numbers have led some
to suspect that children in certain school districts are taking enhancing drugs at the behest
of achievement-oriented parents, or teachers
seeking more orderly classrooms20. Governments may be willing to let competent adults
take certain risks for the sake of enhancement
while restricting the ability to take such risky
decisions on behalf of children.
The third concern is fairness. Consider an
examination that only a certain percentage
can pass. It would seem unfair to allow some,
but not all, students to use cognitive enhancements, akin to allowing some students taking a
maths test to use a calculator while others must
go without. (Mitigating such unfairness may
raise issues of indirect coercion, as discussed
above.) Of course, in some ways, this kind of
unfairness already exists. Differences in education, including private tutoring, preparatory
courses and other enriching experiences give
some students an advantage over others.
Whether the cognitive enhancement is
substantially unfair may depend on its availability, and on the nature of its effects. Does it
actually improve learning or does it just temporarily boost exam performance? In the latter
703

case it would prevent a valid measure of the
competency of the examinee and would
therefore be unfair. But if it were to enhance
long-term learning, we may be more willing
to accept enhancement. After all, unlike athletic competitions, in many cases cognitive
enhancements are not zero-sum games. Cognitive enhancement, unlike enhancement for
sports competitions, could lead to substantive
improvements in the world.
Fairness in cognitive enhancements has a
dimension beyond the individual. If cognitive
enhancements are costly, they may become the
province of the rich, adding to the educational
advantages they already enjoy. One could mitigate this inequity by giving every exam-taker
free access to cognitive enhancements, as some
schools provide computers during exam week
to all students. This would help level the playing field.
Policy governing the use of cognitive
enhancement in competitive situations should
avoid exacerbating socioeconomic inequalities, and should take into account the validity
of enhanced test performance. In developing
policy for this purpose, problems of enforcement must also be considered. In spite of stringent regulation, athletes continue to use, and be
caught using, banned performance-enhancing
drugs.
We call for enforceable policies concerning the use of cognitive-enhancing drugs to
support fairness, protect individuals from
coercion and minimize enhancement-related
socioeconomic disparities.
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policy that is neither laissez-faire nor primarily legislative. We propose to use a variety of
scientific, professional, educational and social
resources, in addition to legislation, to shape
a rational, evidence-based policy informed
by a wide array of relevant experts and stakeholders. Specifically, we propose four types of
policy mechanism.
The first mechanism is an accelerated
programme of research to build a knowledge
base concerning the usage, benefits and associated risks of cognitive enhancements. Good
policy is based on good information, and there
is currently much we do not know about the
short- and long-term benefits and risks of the
cognitive-enhancement drugs currently being
used, and about who is using them and why. For
example, what are the patterns of use outside of
the United States and outside of college communities? What are the risks of dependence when
used for cognitive enhancement? What special
risks arise with the enhancement of children’s
cognition? How big are the effects of currently
available enhancers? Do they change ‘cognitive style’, as well as increasing how quickly
and accurately we think? And given that most
research so far has focused on simple laboratory
tasks, how do they affect cognition in the real
world? Do they increase the total knowledge
and understanding that students take with
them from a course? How do they affect various
aspects of occupational performance?
We call for a programme of research into the
use and impacts of cognitive-enhancing drugs
by healthy individuals.
The second mechanism is the participation of relevant professional organizations
Maximum benefit, minimum harm
in formulating guidelines for their
The new methods of cognitive enhancement are ‘disruptive technologies’
members in relation to cognitive
that could have a profound
enhancement. Many difeffect on human life in the
ferent professions have a
twenty-first century. A
role in dispensing, using
laissez-faire approach
or working with peoto these methods will
ple who use cognitive
leave us at the mercy
enhancers. By creating
of powerful market
policy at the level of
forces that are bound
professional societies,
to be unleashed by the
it will be informed by
promise of increased
the expertise of these
professionals, and their
productivity and competitive advantage. The concerns
commitment to the goals of
their profession.
about safety, freedom and fairness, just reviewed, may well
One group to which this
recommendation applies is
seem less important than the The prescription drug Ritalin is
attractions of enhancement, illegally traded among students. physicians, particularly in
for sellers and users alike.
primary care, paediatrics and
Motivated by some of the same considera- psychiatry, who are most likely to be asked for
tions, Fukuyama21 has proposed the formation cognitive enhancers. These physicians are someof new laws and regulatory structures to protect times asked to prescribe for enhancement by
against the harms of unrestrained biotechno- patients who exaggerate or fabricate symptoms
logical enhancement. In contrast, we suggest a of ADHD, but they also receive frank requests,
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as when a patient says “I know I don’t meet diagnostic criteria for ADHD, but I sometimes have
trouble concentrating and staying organized,
and it would help me to have some Ritalin on
hand for days when I really need to be on top of
things at work.” Physicians who view medicine
as devoted to healing will view such prescribing
as inappropriate, whereas those who view medicine more broadly as helping patients live better
or achieve their goals would be open to considering such a request22. There is certainly a precedent for this broader view in certain branches
of medicine, including plastic surgery, dermatology, sports medicine and fertility medicine.
Because physicians are the gatekeepers to
medications discussed here, society looks to
them for guidance on the use of these medications and devices, and guidelines from other
professional groups will need to take into
account the gatekeepers’ policies. For this reason, the responsibilities that physicians bear for
the consequences of their decisions are particularly sensitive, being effectively decisions for all
of us. It would therefore be helpful if physicians
as a profession gave serious consideration to
the ethics of appropriate prescribing of cognitive enhancers, and consulted widely as to how
to strike the balance of limits for patient benefit
and protection in a liberal democracy. Examples of such limits in other areas of enhancement
medicine include the psychological screening of
candidates for cosmetic surgery or tubal ligation,
and upper bounds on maternal age or number
of embryos transferred in fertility treatments.
These examples of limits may not be specified by
law, but rather by professional standards.
Other professional groups to which this
recommendation applies include educators
and human-resource professionals. In different ways, each of these professions has responsibility for fostering and evaluating cognitive
performance and for advising individuals who
are seeking to improve their performance, and
some responsibility also for protecting the
interests of those in their charge. In contrast
to physicians, these professionals have direct
conflicts of interest that must be addressed in
whatever guidelines they recommend: liberal
use of cognitive enhancers would be expected
to encourage classroom order and raise standardized measures of student achievement, both
of which are in the interests of schools; it would
also be expected to promote workplace productivity, which is in the interests of employers.
Educators, academic admissions officers and
credentials evaluators are normally responsible
for ensuring the validity and integrity of their
examinations, and should be tasked with formulating policies concerning enhancement by
test-takers. Laws pertaining to testing accommodations for people with disabilities provide
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When should cognitive-enhancing
drugs be permitted in the classroom?

a starting point for discussion of some of the would be naive to expect rapid or revolutionary
key issues, such as how and when enhance- change in the laws governing the use of controlments undermine the validity of a test result led substances. Nevertheless, these laws should
and the conditions under which enhancement be adjusted to avoid making felons out of those
should be disclosed by a test-taker.
who seek to use safe cognitive enhancements.
The labour and professional organizations And regulatory agencies should allow pharof individuals who are candidates for on-the- maceutical companies to market cognitivejob cognitive enhancement make up our final enhancing drugs to healthy adults provided
category of organization that should formu- they have supplied the necessary regulatory
late enhancement policy. From assembly line data for safety and efficacy.
workers to surgeons, many different kinds of
We call for careful and limited legislative
employee may benefit from enhancement and action to channel cognitive-enhancement
want access to it, yet they may also need protec- technologies into useful paths.
tion from the pressure to enhance.
We call for physicians, educators, regulators Conclusion
and others to collaborate in developing poli- Like all new technologies, cognitive enhancecies that address the use of cognitive-enhanc- ment can be used well or poorly. We should
ing drugs by healthy individuals.
welcome new methods of improving our brain
The third mechanism is education to function. In a world in which human workincrease public understanding of cognitive spans and lifespans are increasing, cognitive
enhancement. This would be proenhancement tools — including
vided by physicians, teachers, colthe pharmacological — will be
“Many kinds of
lege health centres and employers,
increasingly useful for improved
employee may
similar to the way that information
quality of life and extended work
benefit from
about nutrition, recreational drugs
productivity, as well as to stave
and other public-health informaoff normal and pathological ageenhancement.”
tion is now disseminated. Ideally it
related cognitive declines23. Safe
would also involve discussions of different ways and effective cognitive enhancers will benefit
of enhancing cognition, including through both the individual and society.
adequate sleep, exercise and education, and an
But it would also be foolish to ignore probexamination of the social values and pressures lems that such use of drugs could create or
that make cognitive enhancement so attractive exacerbate. With this, as with other technoloand even, seemingly, necessary.
gies, we need to think and work hard to maxiWe call for information to be broadly mize its benefits and minimize its harms. ■
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